產(chǎn)品描述: | Tiratricol is a metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome. |
靶點: |
Thyroid hormone receptor(THR);Thyroidhormonereceptor(THR) |
體內(nèi)研究: |
研究表明,Tiratricol可使甲狀腺腫減少,對皮質(zhì)類固醇激素使用降低引起的萎縮也有一定效果。Tiratricol可治療甲狀腺激素抵抗綜合征,結(jié)合甲狀腺素抑制甲狀腺癌患者體內(nèi)促甲狀腺激素的產(chǎn)生 |
參考文獻: |
1.Carvalho GA, et al. Arq Bras Endocrinol Metabol, 2004, 48(1), 83-92. 2.Brenta G, et al. J Clin Endocrinol Metab, 2003, 88(11), 5287-5292. 3.Yazdanparast P, et al. Thyroid, 2006, 16(11), 1157-1162. |
溶解性: |
DMSO:93 mg/mL (149.5 mM) Ethanol:93 mg/mL (149.5 mM) H2O:<1 mg/mL |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.608 ml |
8.039 ml |
16.079 ml |
5 mM |
0.322 ml |
1.608 ml |
3.216 ml |
10 mM |
0.161 ml |
0.804 ml |
1.608 ml |
50 mM |
0.032 ml |
0.161 ml |
0.322 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |